Introduction
============

Hyperbaric oxygen (HBO~2~) treatment, defined as breathing 100% oxygen at pressures greater than 1.4 atmospheres absolute, is used for 14 indications approved by the Undersea and Hyperbaric Medical Society (UHMS), such as soft tissue radiation injury and enhancement of healing in selected problem wounds (see [Table 1](#table1){ref-type="table"}) \[[@ref1]\]. HBO~2~ greatly increases the amount of oxygen dissolved in plasma and is effective at relieving hypoxia. This effect is useful in conditions such as ischemic wounds or compromised flaps or grafts, where inadequate oxygenation is a factor. Laboratory studies also suggest HBO~2~ has actions beyond the relief of hypoxia (eg, promoting angiogenesis in irradiated tissue, anti-inflammatory effects, radiosensitization of tumors, hypoxia preconditioning, and fungal growth inhibition) and has potential to treat other currently unapproved conditions, such as inflammatory bowel disease and pyoderma gangrenosum \[[@ref2]-[@ref4]\]. Approximately 1350 hyperbaric chamber facilities exist in the United States, and outpatient facility claims for hyperbaric services to Medicare alone totaled US \$178 million in 2015. Although HBO~2~ treatment is used for a variety of indications, much of the evidence to support its use is based on small trials, case series, and retrospective studies (see [Table 1](#table1){ref-type="table"}) \[[@ref2],[@ref5]-[@ref11]\].

This inconsistent evidence base has led to a range of opinions about when and how HBO~2~ should be used. For example, a common application of HBO~2~ is in treating radiation cystitis, which is supported by most insurance policies in the United States \[[@ref12],[@ref13]\]. The evidence base and practice patterns are strong enough that when a randomized trial of HBO~2~ for radiation cystitis was attempted (ie, ClinicalTrials.gov Identifier: NCT00134628), the trial had to be closed due to poor recruitment. It was difficult to find patients who were willing to be randomized to placebo treatment and providers who were willing to refer them. In one review describing the many treatment options for radiation cystitis, the authors concluded "there are currently no adequate treatment options." They cited HBO~2~ response rates between 27% and 92%, and recurrence rates after treatment from 8% to 63% \[[@ref14]\]. The lower end of this response rate range suggests HBO~2~ should only be tried occasionally for selected patients, while the higher end argues that HBO~2~ should be the treatment of choice. The largest prospective study of HBO~2~ treatment for radiation cystitis included in that review was based on 40 patients \[[@ref12]\]. Since that review, five Nordic university hospitals were able to complete a randomized trial for radiation cystitis, although they excluded from enrollment patients with severe ongoing bleeding (ie, the patients where the impact from HBO~2~ treatment would be most meaningful). The trial showed benefit from HBO~2~ \[[@ref15]\].

This diversity of opinion and practice creates a difficult situation where the published evidence base is small, but advancing to large-scale clinical trials has been difficult. Also, hyperbaric centers worldwide are being asked to provide a stronger level of evidence to support the treatments they deliver. For example, the National Health Service (NHS) England will now support the routine use of HBO~2~ treatment only for decompression illness and gas embolism \[[@ref16]\]. Conditions reviewed and not recommended for routine hyperbaric therapy because of the perceived lack of reliable outcome data include the UHMS-approved indications of carbon monoxide poisoning, soft tissue radiation damage, and necrotizing soft tissue infections. A new approach is needed to collect outcome data for HBO~2~ treatments.

The study of HBO~2~ treatment presents unique challenges. Because HBO~2~ treatment usually requires daily treatments over the course of 1-2 months in a hyperbaric chamber, single hyperbaric centers typically do not treat large numbers of patients and cannot accrue sufficient numbers to conduct credible studies. Furthermore, because patients are referred for treatment from other specialties, follow-up tends to be conducted by the referring specialist, and outcome data are not available to the hyperbaric program beyond the treatment period. Obtaining meaningful data on HBO~2~ outcomes requires pooling of data from multiple centers and establishing an infrastructure of centers motivated to conduct research and initiate long-term follow-up. The HBO~2~ Registry Consortium described here will provide this framework for urgently needed evaluative observational studies, with the potential to improve the clinical application of HBO~2~ dramatically. In addition, the consortium will provide an efficient platform for conducting trials on a wide range of HBO~2~ indications, as well as studies of the molecular underpinnings of the treatment itself. This consortium infrastructure could be used to develop the platform from which multiple studies could be conducted at much lower cost.

###### 

Indications for hyperbaric oxygen (HBO~2~) therapy with Undersea and Hyperbaric Medical Society (UHMS) assessment of the quality and strength of evidence from the UHMS Indications report \[[@ref1]\].

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Indication^a^                       UHMS assessment of evidence:quality^b^, strength^c^   Notes relevant to the registry                              
  ----------------------------------- ----------------------------------------------------- ----------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------
  **UHMS-approved indications**       \                                                     \                                                           

  \                                   Acute thermal burn injury                             A, IIa                                                      Used only at certain centers; need to combine data from centers

  \                                   Air or gas embolism                                   C-LD, I                                                     Individual centers likely to see indication only occasionally

  \                                   Carbon monoxide                                       A, IIa                                                      Sporadic cases at multiple centers

  \                                   Central retinal artery occlusion                      C-LD, IIb                                                   Sporadic cases at multiple centers

  \                                   Compromised grafts and flaps                          C-LD, IIa                                                   Diverse presentations; registry good for retrospective as well as prospective analysis

  \                                   Crush injury and compartment syndrome                 B-R, I                                                      Used at some centers and not others

  \                                   Decompression sickness                                C-LD, I                                                     Use is concentrated at certain centers

  \                                   Delayed radiation injury                              B-R to C-LD depending on site, I to IIb depending on site   Registry can offer consistent outcome tracking across centers

  \                                   Enhancement of healing in selected problem wounds     A, I for diabetic foot ulcers\                              Common use of HBO~2~; registry can offer consistent outcome measures needed across sites
                                                                                            B-NR, IIb for others                                        

  \                                   Gas gangrene                                          B-NR, I                                                     Sporadic cases at multiple centers

  \                                   Idiopathic sudden sensorineural hearing loss          A, IIa                                                      Used regularly at some centers and not at others

  \                                   Intracranial abscess                                  C-LD, IIb                                                   Sporadic cases at multiple centers

  \                                   Necrotizing soft tissue infections                    B-NR, IIa                                                   Sporadic cases at multiple centers

  \                                   Chronic refractory osteomyelitis                      B-NR, IIa to IIb depending on site                          Sporadic cases at multiple centers

  \                                   Severe anemia                                         C-LD, IIb                                                   Individual centers likely to see indication only occasionally

  **Non-UHMS-approved indications**   \                                                     \                                                           

  \                                   Calciphylaxis                                         Not rated                                                   No randomized controlled trials for any treatment modality; recommended as second-line therapy \[[@ref5]\]

  \                                   COVID-19^d^                                           Not rated                                                   Case series show benefit \[[@ref6],[@ref7]\]

  \                                   Crohn disease                                         Not rated                                                   Benefit seen in case reports and case series \[[@ref8]\]

  \                                   Frostbite                                             Not rated                                                   Multiple case reports show benefit; often classified as part of *acute traumatic ischemia*, like crush injury

  \                                   Otitis externa                                        Not rated                                                   Case reports show benefit; Cochrane report recommends further research \[[@ref9]\]

  \                                   Peripheral vascular disease--related ulcer            Not rated                                                   HBO~2~ may be beneficial in selected cases

  \                                   Pneumatosis intestinalis                              Not rated                                                   Multiple case reports show benefit \[[@ref10]\]

  \                                   Pyoderma gangrenosum                                  Not rated                                                   Multiple case reports show benefit

  \                                   Raynaud syndrome                                      Not rated                                                   Case reports and case series show benefit \[[@ref11]\]

  \                                   Ulcerative colitis                                    Not rated                                                   Recent randomized trial shows benefit for acute flares \[[@ref2]\]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Many of these indications are only seen episodically at any given center, so a registry is important for aggregating a sufficient number of cases to draw conclusions.

^b^Quality of evidence has five levels---Level A: highest quality, where evidence comes from more than one randomized controlled trial, a meta-analysis of high-quality randomized controlled trials, or one or more randomized controlled trials corroborated by high-quality registry studies; Level B-R: evidence comes from randomized trials; Level B-NR: evidence comes from nonrandomized trials; Level C-LD: evidence comes from limited data; and Level C-EO: evidence comes from expert opinion.

^c^Strength of evidence is classified as Class I: Strong; Class IIa: Moderate; Class IIb: Weak; Class III: No benefit; and Class III: Harm.

^d^COVID-19: coronavirus disease 2019.

Beyond the fundamental question of whether HBO~2~ treatment should be recommended for given indications, the HBO~2~ community needs data to answer more detailed questions, such as: Are some forms of radiation injury (eg, brain radionecrosis) more or less responsive than others to HBO~2~ treatment? Are some patients more likely than others to benefit from HBO~2~ for a given indication, and can those patients be identified? Having identified the patients most likely to benefit from treatment, can trials be designed more effectively to test HBO~2~ treatment (eg, crossover trials)? A well-designed registry can provide the data required to answer these questions.

Methods
=======

Overview
--------

This paper outlines the development of an international, multicenter, prospective registry consortium. A center joins the consortium by signing the consortium agreement. This agreement covers membership, governance, data sharing requirements, use of member data, publications, intellectual property, liability, confidentiality, and insurance. Data are collected using Research Electronic Data Capture (REDCap), a widely available, easily accessible, Health Insurance Portability and Accountability Act (HIPAA)-compliant, web-based data collection system \[[@ref17]\]. Each participating center determines its own start date for data collection (ie, *reference date*) and records baseline data for every patient referred to the treatment center, whether or not treatment is indicated for, or accepted by, the patient after that start date. Patients included in the registry are those patients who have been evaluated for possible treatment of any UHMS-approved condition, or any non-UHMS-approved condition, including those who are part of research studies or trials. The registry gathers data on whether the evaluation determined that treatment was contraindicated, indicated and scheduled, or indicated but declined by the patient.

Each center's participation is overseen by its own US Institutional Review Board (IRB) or the country-specific equivalent, or a center can opt to rely on the Dartmouth Committee for the Protection of Human Subjects (ie, the Dartmouth IRB). The REDCap-based data collection template is the same at all centers, so all centers collect the same outcome measures. Quarterly, each center performs a deidentified data download from their REDCap database to the coordinating center's REDCap database at Dartmouth College. These deidentified data from each center are combined into a single REDCap database, which is the multicenter data registry. Optional consent for longer-term follow-up is being pilot tested at one center.

Data Collected
--------------

The design approach to the registry is to create a system that can be used at any hyperbaric center. This means the system must be low cost and not require excessive staff effort. Although gathering data from electronic medical record systems is desirable to avoid repeated data entry, this is not practical for this project due to the diversity of medical record systems and the level of effort and funding required to standardize and update outcome measures and procedures among them. To minimize staff effort, data entry needs to be minimal, which means extensive data on comorbid conditions, medications, and medical history cannot be collected. Instead, the registry has to focus on a few key outcome measures whose data any center can collect and enter reliably. For studies using registry data where more information on the individual patients is needed, an interested investigator can obtain IRB or ethics approval to work with more detailed data at the individual centers using procedures outlined in the consortium agreement.

The registry database was initially designed by a consensus of founding members of the HBO~2~ research consortium---the Geisel School of Medicine at Dartmouth in Hanover, New Hampshire, and the Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire---and core data are collected for UHMS-approved and some nonapproved conditions. Data are collected using four main data collection instruments (see [Table 2](#table2){ref-type="table"}). The Demographics instrument collects demographic information as well as information on insurance and distance traveled. The Pre Treatment Information instrument collects information on the condition being treated, treatments prescribed and administered, and subjective and objective measurements of the patient's status at treatment start. A quality-of-life measure---the EuroQol, 5-dimension, 5-level (EQ-5D-5L)---is also administered at baseline on all patients \[[@ref18],[@ref19]\] as part of the Pre Treatment Information instrument. The Pre Surgical Information instrument collects subjective and objective measures of the patient's status prior to a surgical intervention (eg, tooth extraction) if one is performed. The Treatment and Outcomes instrument repeats information collection of the Pre Treatment Information outcome measures, records the actual treatment given, asks about complications, and repeats the quality-of-life questionnaire.

Both indication-specific outcomes and general outcomes are collected, including HBO~2~ treatment complications (eg, changes in refraction, seizures, pneumothorax, confinement anxiety, barotrauma, and placement of pressure-equalization tubes in the ear). Wherever possible, common objective outcome measures are used. The registry uses validated questionnaires that have supporting evidence in the literature (eg, the Common Terminology Criteria for Adverse Events \[CTCAE\] hematuria grading scale for radiation cystitis and the European Organisation for Research and Treatment of Cancer \[EORTC\] Quality of Life Questionnaire Head and Neck \[QLQ-H&N35\] for head and neck symptoms) \[[@ref20],[@ref21]\] as well as some questionnaires that were custom developed for the registry (see [Table 2](#table2){ref-type="table"}) \[[@ref22]-[@ref24]\]. Factors that might affect the effectiveness of the therapy are also collected (eg, diabetes, smoking, and other nicotine use). Future plans, including long-term follow-up and linkage to cancer registries and vital status data, depend on future funding. [Table 3](#table3){ref-type="table"} lists the parameters measured \[[@ref25],[@ref26]\].

###### 

Data collection instruments and questionnaires used in the registry. Patient-reported outcomes are used in the registry whenever possible.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Instruments and questionnaires            Details^a^                                          
  ----------------------------------------- --------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------
  **Data collection instruments**                                                               

  \                                         Demographics                                        Age, race, ethnicity, biological sex, insurance, and driving distance; personal health information is only kept at individual centers

  \                                         Pre Treatment Information                           Referral reason, urgency, diabetes, smoking, nicotine, indication, baseline questionnaires and outcome information, EQ-5D-5L^b^, and prescribed treatment

  \                                         Pre Surgical Information                            Outcome measures prior to intervention if one is performed (eg, tooth extraction, mandibular reconstruction, etc)

  \                                         Treatment and Outcomes                              Treatment given, complications experienced, and outcome measures

  **Questionnaires used in the registry**   \                                                   

  \                                         Bladder Questionnaire (radiation cystitis)          Seven questions from the Urinary Distress Inventory 6 plus one custom registry question on urinary bleeding \[[@ref24]\]

  \                                         Bowel Symptoms Questionnaire                        Nine questions custom developed for the registry

  \                                         Head and Neck Questionnaire                         37 questions selected from the EORTC^c^ QLQ-H&N35^d^ \[[@ref23]\] and the GRIX^e^ questionnaire \[[@ref22]\]

  \                                         Laryngeal Soft Tissue Radionecrosis Questionnaire   Two questions based on the Chandler \[[@ref20]\] and RTOG^f^ scales \[[@ref21]\]

  \                                         Perianal Crohn's Symptom Index                      11 questions custom developed for the registry
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Details of data collection instruments include the types of data collected; details of questionnaires used in the study; and the sources used to develop the questionnaires.

^b^EQ-5D-5L: EuroQol, 5-dimension, 5-level.

^c^EORTC: European Organisation for Research and Treatment of Cancer.

^d^QLQ-H&N35: Quality of Life Questionnaire Head and Neck.

^e^GRIX: Groningen Radiotherapy-Induced Xerostomia.

^f^RTOG: Radiation Therapy Oncology Group.

###### 

Indications for hyperbaric oxygen (HBO~2~) treatment and outcomes measured for the registry.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Condition                                                                Pre- and posttreatment outcome measurements^a^                                                                                                                                                
  ------------------------------------------------------------------------ ----------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Undersea and Hyperbaric Medical Society (UHMS)-approved conditions**                                                                                                                                                                                                 

  \                                                                        Acute ischemia (not crush injury or compartment syndrome)   Assessment of cyanosis in affected areas pre- and posttreatment and amputations posttreatment                                     

  \                                                                        Acute thermal burn injury                                   Number of wounds and wound measurements                                                                                           

  \                                                                        Air or gas embolism                                         Glasgow Coma Scale score for brain events, troponin for cardiac events, and six-level outcome measure for all                     

  \                                                                        Carbon monoxide                                             Narrative on treatment and outcome                                                                                                

  \                                                                        Central retinal artery occlusion                            Visual acuity (right and left)                                                                                                    

  \                                                                        Compromised grafts and flaps                                Graft and flap assessment (necrosis and color), number of wounds, and wound measurements                                          

  \                                                                        Crush injury and compartment syndrome                       Location, number of wounds, and wound measurements                                                                                

  \                                                                        Decompression sickness                                      Six-level patient outcome measure                                                                                                 

  \                                                                        **Delayed radiation injury**                                \                                                                                                                                 

  \                                                                        \                                                           Brain                                                                                                                             Nine-Hole Peg Test and Trail-Making Test

  \                                                                        \                                                           Larynx                                                                                                                            Laryngeal Soft Tissue Radionecrosis Questionnaire and Head and Neck Questionnaire

  \                                                                        \                                                           Bladder                                                                                                                           Hematuria grade and Bladder Questionnaire

  \                                                                        \                                                           Bowel                                                                                                                             Bowel Questionnaire

  \                                                                        \                                                           Jaw                                                                                                                               Exposed bone percentage coverage if exposed bone present, osteoradionecrosis grade \[[@ref25]\], tooth complications after extraction, and Head and Neck Questionnaire

  \                                                                        Enhancement of healing in selected problem wounds           Number of wounds, wound measurements, Wagner grade, and Strauss score \[[@ref26]\]                                                

  \                                                                        Gas gangrene                                                White blood cell count, number of wounds, wound measurements, and number of surgical interventions                                

  \                                                                        Idiopathic sudden sensorineural hearing loss                Four-frequency pure-tone average and word recognition score                                                                       

  \                                                                        Intracranial abscess                                        Number of surgical interventions                                                                                                  

  \                                                                        Necrotizing soft tissue infections                          White blood cell count, number of wounds, wound measurements, and number of surgical interventions                                

  \                                                                        Chronic refractory osteomyelitis                            White blood cell count, C-reactive protein, and number of surgical interventions                                                  

  \                                                                        Severe anemia                                               Hemoglobin; markers of end-organ damage; and narrative on treatment, complications, and outcome                                   

  **Conditions not currently UHMS approved**                               \                                                                                                                                                                                             

  \                                                                        Calciphylaxis                                               Location, number of wounds, wound measurements, number of surgical interventions, and subjective assessment at end of treatment   

  \                                                                        COVID-19^b^                                                 Pulse oximetry pre- and posttreatment, respiratory rate pre- and posttreatment, and pretreatment oxygen                           

  \                                                                        Crohn disease                                               Perianal Crohn's Symptom Index and Bowel Questionnaire                                                                            

  \                                                                        Frostbite                                                   Number of wounds, wound measurements, and number of surgical interventions                                                        

  \                                                                        Malignant otitis externa                                    Narrative on treatment and outcome                                                                                                

  \                                                                        Peripheral vascular disease--related ulcer                  Number of wounds, wound measurements, and number of surgical interventions                                                        

  \                                                                        Pneumatosis intestinalis                                    Narrative on treatment and outcome                                                                                                

  \                                                                        Pyoderma gangrenosum                                        Number of wounds, wound measurements, and number of surgical interventions                                                        

  \                                                                        Raynaud syndrome                                            Number of wounds, wound measurements, and number of surgical interventions                                                        

  \                                                                        Ulcerative colitis                                          Bowel Questionnaire                                                                                                               
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^All patients will complete a quality-of-life questionnaire---the EuroQol, 5-dimension, 5-level (EQ-5D-5L) \[[@ref19]\]---at the start and end of treatment. Text entries are available for all indications to provide more detail about the cases.

^b^COVID-19: coronavirus disease 2019.

Governance
----------

The HBO~2~ Registry Consortium includes member institutions fulfilling the requirements as shown in [Textbox 1](#box1){ref-type="boxed-text"}. A steering committee is responsible for the governance of the registry. The Geisel School of Medicine at Dartmouth and the Dartmouth-Hitchcock Medical Center are the founding members of the consortium and each have representatives on the steering committee. The steering committee also includes a representative from each participating center. By a majority vote, with affirmative votes from the founding members, the steering committee has the authority to set the strategic direction for the registry, admit or remove members, set membership fees, establish policies, and relocate the registry. Member-initiated research protocols are approved by a majority vote of the steering committee. The committee also votes on any changes to the REDCap data collection instruments. The steering committee meets annually at the UHMS annual meeting, where changes and modifications to the registry are discussed and voted upon. Template IRB application materials are freely shared between participating centers.

###### Requirements and activities of participating centers of the HBO~2~ Registry Consortium.

Center characteristic:

-   Hyperbaric oxygen (HBO~2~) treatment program

Administrative requirements:

-   Ethics Committee approval, either by relying on Dartmouth or at own center

-   Execution of consortium agreement, which includes agreement to share deidentified data with coordinating center and willingness to have data used for registry purposes

-   Installation of, or access to, Research Electronic Data Capture (REDCap) database at the center or establishment of procedures and authorization to enter patient data securely into REDCap database hosted by another participating center

Data collection activities:

-   Patient informed consent or waived consent, depending on Ethics Committee requirement

-   Prospective data entry for all patients evaluated at the center; if consent is not waived, need to have 95% or greater participation over a year

-   Administration of indication-specific questionnaires and/or collection of outcome measurement data before and after treatment

-   Completion of annual audit and quality assurance processes; responsiveness to feedback on data quality and attainment of defined minimum data-quality standards

-   Quarterly submission of deidentified patient data to coordinating center at Dartmouth College

-   Option to participate in research studies, grant writing, or fundraising efforts

Statistical Analysis
--------------------

Descriptive analyses will be conducted to describe the baseline characteristics and outcomes of patients with each indication, overall and by center, including the numbers, proportions, and confidence intervals for the following: patients with each indication for treatment; those evaluated who were not treated or who were partially treated and the reasons why; baseline characteristics, including referral information and baseline outcome measures; treatments given; occurrence of each type of side effect; and outcome measures at the end of treatment with change scores and relative change scores, as appropriate. For measures with numerical scores, we will assess absolute and relative changes; for other measures, we will report outcomes in terms of the proportions with symptom resolution, improvement, no change, or deterioration. Factors associated with key outcomes will be explored using multifactorial analyses where sample size is sufficient for models to be stable. All results will be presented and discussed in terms of estimates and 95% confidence intervals to avoid focusing on *P* values alone.

Results
=======

Data collection started within the registry at the Dartmouth-Hitchcock Medical Center as a pilot project in 2012. During this time, the consortium agreement was developed and processes were established to enroll other centers. In 2019, four additional centers began entering patient data. Currently, the registry has 919 individual patient entries from four centers, with the majority from the Dartmouth-Hitchcock Medical Center (n=621). Over time, the registry is gradually collecting sufficient data to robustly explore changes before and after HBO~2~ treatment. [Figure 1](#figure1){ref-type="fig"}, for example, shows the results for the Head and Neck Questionnaire before and after HBO~2~ treatment. [Figure 2](#figure2){ref-type="fig"} shows changes in patient-reported symptoms of xerostomia (ie, dry mouth) after receiving HBO~2~ treatment. These responses are important because whether HBO~2~ treatment has an effect on xerostomia has been a longstanding question in the HBO~2~ field \[[@ref27]\]. [Figure 3](#figure3){ref-type="fig"} shows changes in the hematuria score for those patients undergoing treatment with HBO~2~ for radiation cystitis. [Figure 4](#figure4){ref-type="fig"} shows the experience to date for patients treated for idiopathic sudden sensorineural hearing loss. These preliminary results show that the registry is useful for tracking trends in outcomes and patient-reported symptoms after HBO~2~ treatment. As further patient experiences are collected, these data will also be used in retrospective analyses to determine the characteristics of those patients who responded well and of those who did not.

![Delayed radiation injury. Scores on the Head and Neck Questionnaire before and after hyperbaric oxygen (HBO~2~) are shown: lower scores indicate fewer symptoms. This questionnaire is administered to any patient who had experienced head and neck radiation and is being treated for radiation injury in the head and neck region. Although responses vary between patients, results show lower scores posttreatment (16.9 pretreatment to 14.3 posttreatment, *P*=.03, Wilcoxon signed-rank test). By identifying patients who did not respond or who worsened, these data can guide further analyses.](resprot_v9i8e18857_fig1){#figure1}

![Delayed radiation injury. Scores on the xerostomia (ie, dry mouth) questions within the Head and Neck Questionnaire are shown: lower scores indicate fewer symptoms. Dry mouth is a common complication of head and neck radiation, and whether hyperbaric oxygen (HBO~2~) helps with this symptom is an open question. Early results from the registry suggest improvement (11.9 pretreatment to 8.9 posttreatment, *P*=.01, Wilcoxon signed-rank test).](resprot_v9i8e18857_fig2){#figure2}

![Delayed radiation injury, radiation cystitis. Scores on the hematuria scale before and after hyperbaric oxygen (HBO~2~) treatment are shown: 0=no hematuria, 1=microscopic hematuria, 2=occasional macroscopic hematuria, 3=frequent macroscopic hematuria, and 4=severe hemorrhagic cystitis. Most patients see an improvement in hematuria score (2.5 pretreatment to 1.0 posttreatment, *P*\<.001, Wilcoxon signed-rank test). As the number of entries in the registry grows, these data may be useful for assessing the number of treatments needed for successful outcomes.](resprot_v9i8e18857_fig3){#figure3}

![Idiopathic sudden sensorineural hearing loss. Four-frequency pure-tone averages on audiometry before and after hyperbaric oxygen treatment (HBO~2~) are shown: a lower number indicates an improvement in hearing. Most patients are experiencing an improvement in audiometric thresholds (89.9 dB hearing loss \[HL\] pretreatment to 72.3 dB HL posttreatment, *P*=.03, Wilcoxon signed-rank test). As the number of cases in the registry grows, these data could be used to assess how long after the hearing loss HBO~2~ may be useful.](resprot_v9i8e18857_fig4){#figure4}

Discussion
==========

Principal Findings
------------------

An HBO~2~ treatment outcomes registry is feasible and can provide consistently recorded outcomes from HBO~2~ treatments at multiple centers. Initial analyses of some of the outcome data are already showing significant changes after HBO~2~ treatment.

Strengths of the Registry
-------------------------

A key strength of the registry is its use of REDCap \[[@ref17]\], a free, secure, web-based, data collection system used to build and manage online surveys and databases in more than 3964 centers worldwide. The HBO~2~ REDCap database has been pilot tested and revised at the coordinating center for 6 years, and core variables have been collected on UHMS-approved indications for HBO~2~ treatment, as well as some non-UHMS-approved indications. The database includes 1996 variables, many of which are disease specific and are programmed to appear only for particular indications or situations (ie, during data entry, a staff member will only be entering data on a small subset of the variables available). Data entry takes an average of 15 minutes per case, distributed over several clinical visits. The template for the database can be exported to Excel, emailed to another center, and easily uploaded to create an identical registry that is ready for data entry. REDCap provides the ability to perform a deidentified data export from each participating center. This is sent to a central, pooled REDCap database at the Geisel School of Medicine at Dartmouth. Because of the simplicity of the software and the relatively low burden of data entry, the registry is relatively inexpensive for new centers to install and maintain. Because only deidentified data are pooled, the risk to participants is minimal.

Limitations of the Registry
---------------------------

At present, the registry is following individuals who receive HBO~2~ treatment, and a registry of similar patients with similar conditions who are not receiving HBO~2~ treatment does not exist. Therefore, there is no way to compare outcomes from HBO~2~ treatment directly with outcomes from similar patients who did not receive the treatment. As the registry grows, an additional limitation will be funding, which will be needed to maintain a system of data-quality oversight, analysis, longer-term follow-up, and other registry-related activities.

Conclusions
-----------

An outcome-focused registry for HBO~2~ treatment is needed urgently to provide both patients and providers with the information they need to decide whether and how to use HBO~2~ treatment. To be successful, this registry must be practical, easy to use, and easily expandable. The registry described here meets these requirements. The data entry requirements are not excessive and should be within the capabilities of existing staff at any given hyperbaric center. Also, by using REDCap, the registry can be expanded to include detailed information on particular indications and long-term follow-up on selected patients without significantly increasing the basic data entry requirements.
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